“Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues.”, J Infect Dis, vol. 202, no. 11, pp. 1649-58, 2010.
, “B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine.”, Clin Vaccine Immunol, vol. 24, no. 5, 2017.
, “Dose-dependent neutralizing-antibody responses to vaccinia.”, J Infect Dis, vol. 189, no. 3, pp. 493-7, 2004.
, “Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.”, J Infect Dis, vol. 193, no. 9, pp. 1223-8, 2006.
, “Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans.”, J Infect Dis, vol. 197, no. 4, pp. 580-3, 2008.
, “Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.”, J Infect Dis, vol. 198, no. 5, pp. 635-41, 2008.
, “Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults.”, J Infect Dis, vol. 211, no. 6, pp. 870-8, 2015.
, “A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults.”, J Infect Dis, vol. 210, no. 11, pp. 1763-71, 2014.
, “Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults.”, Vaccine, vol. 27, no. 37, pp. 5091-5, 2009.
, “Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.”, J Infect Dis, vol. 198, no. 9, pp. 1309-16, 2008.
, “Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.”, N Engl J Med, vol. 354, no. 13, pp. 1343-51, 2006.
,